PANG Stock Overview
Pangaea Oncology, S.A., a medical services company, provides a range of services to cancer patients in Spain and the rest of European Union countries.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Pangaea Oncology, S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €1.71 |
| 52 Week High | €2.42 |
| 52 Week Low | €1.68 |
| Beta | 0.016 |
| 1 Month Change | -8.06% |
| 3 Month Change | -2.84% |
| 1 Year Change | -10.47% |
| 3 Year Change | -25.65% |
| 5 Year Change | -16.99% |
| Change since IPO | -39.58% |
Recent News & Updates
Shareholder Returns
| PANG | ES Life Sciences | ES Market | |
|---|---|---|---|
| 7D | -8.1% | -5.1% | 3.3% |
| 1Y | -10.5% | -9.0% | 15.5% |
Return vs Industry: PANG exceeded the Spanish Life Sciences industry which returned -8% over the past year.
Return vs Market: PANG underperformed the Spanish Market which returned 16.1% over the past year.
Price Volatility
| PANG volatility | |
|---|---|
| PANG Average Weekly Movement | 2.5% |
| Life Sciences Industry Average Movement | 6.3% |
| Market Average Movement | 3.3% |
| 10% most volatile stocks in ES Market | 6.5% |
| 10% least volatile stocks in ES Market | 0.9% |
Stable Share Price: PANG has not had significant price volatility in the past 3 months.
Volatility Over Time: PANG's weekly volatility (2%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | 58 | Javier Rivela-Rodriguez | www.panoncology.com |
Pangaea Oncology, S.A., a medical services company, provides a range of services to cancer patients in Spain and the rest of European Union countries. The company offers molecular diagnostics, such as mutation analysis in tumor tissue and blood, gene amplification and translocation testing, immunohistochemistry, and gene expression; clinical trials; in vitro drug profiling, including MTT proliferation assays, western blotting, colony formation, migration and invasion assays, and gene silencing; and Dx platform, which performs companion diagnostic platform validation, validation against commercially available platforms, and Ad-hoc R+D for diagnostics companies. It also provides biomarker discovery to identify novel targets for targeted therapies in pre-clinical development.
Pangaea Oncology, S.A. Fundamentals Summary
| PANG fundamental statistics | |
|---|---|
| Market cap | €50.35m |
| Earnings (TTM) | -€2.70m |
| Revenue (TTM) | €6.79m |
7.4x
P/S Ratio-18.6x
P/E RatioIs PANG overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PANG income statement (TTM) | |
|---|---|
| Revenue | €6.79m |
| Cost of Revenue | €2.78m |
| Gross Profit | €4.01m |
| Other Expenses | €6.71m |
| Earnings | -€2.70m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.092 |
| Gross Margin | 59.08% |
| Net Profit Margin | -39.85% |
| Debt/Equity Ratio | 11.8% |
How did PANG perform over the long term?
See historical performance and comparison